Anúncio
Anúncio
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
4.21
USDPatrocinado
+0.12
+2.81%
02 de jan., 15:58 UTC -5
Encerrado
Pós-Mercado
4.22
+0.02
+0.48%
Relatórios de Lucros RXRX
Rácio de surpresa positiva
RXRX separação 11 de 18 últimas estimativas.
61%
Próximo Relatório
Data do Próximo Relatório
26 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$25.08M
/-$0.32
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+384.59%
/-11.11%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+455.92%
/-39.62%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On 05 de nov. de 2025, RXRX reported earnings of -0.36 USD per share (EPS) for Q3 25, beating the estimate of -0.37 USD, resulting in a 4.61% surprise. Revenue reached 5.17 milhão, compared to an expected 17.32 milhão, with a -70.13% difference. The market reacted with a -0.80% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.32 USD, with revenue projected to reach 25.08 milhão USD, implying an diminuir of -11.11% EPS, and aumentar of 384.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.36, beating estimates by 4.61%, and revenue of $5.17M, -70.13% below expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -0.8%, changed from $5.00 before the earnings release to $4.96 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for 26 de fev. de 2026.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 10
analistas, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.32 and revenue of $25.08M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio